公开(公告)号：US20230051268A1

公开(公告)日：2023-02-16

申请号：US17757672

申请日：2020-12-18

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Andrew SATLIN ,  Margaret MOLINE ,  Ishani LANDRY

IPC: A61K31/506 ,  A61K9/00

Abstract: Disclosed are methods for treating insomnia, comprising administering orally a dosage form comprising Lemborexant or a pharmaceutically acceptable salt thereof to a patient in need thereof at a single daily dose ranging from 5 mg to 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof, provided that the maximum dose is 5 mg once per day of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof when the patient has moderate hepatic impairment classified in Child-Pugh class B under Child-Pugh Classification.

公开(公告)号：US20250163135A1

公开(公告)日：2025-05-22

申请号：US18577174

申请日：2022-07-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Chad SWANSON ,  Akihiko KOYAMA ,  Michio KANEKIYO ,  Michael IRIZARRY ,  Lynn KRAMER ,  June KAPLOW ,  David VERBEL ,  Shobha DHADDA ,  Pallavi SACHDEV ,  Larisa REYDERMAN ,  Seiichi HAYATO, ,  Ishani LANDRY ,  Robert GORDON

IPC: C07K16/18 ,  A61K39/00 ,  G01N33/68

Abstract: Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.

公开(公告)号：US20250051427A1

公开(公告)日：2025-02-13

申请号：US18720518

申请日：2022-11-08

Applicant: EISAI R&D MANAGEMENT CO., LTD. ,  WASHINGTON UNIVERSITY

Inventor： Larisa REYDERMAN ,  Jin ZHOU ,  Lynn KRAMER ,  Michael IRIZARRY ,  Pallavi SACHDEV ,  Shobha DHADDA ,  David LI ,  Kristin WILDSMITH ,  Pau ACEVES BALDO ,  Sumit RAWAL ,  Akihiko KOYAMA ,  Chad SWANSON ,  Michio KANEKIYO ,  June KAPLOW ,  David VERBEL ,  Ishani LANDRY ,  Seiichi HAYATO ,  Robert GORDON ,  Randall BATEMAN ,  Eric MCDADE

IPC: C07K16/18 ,  A61K39/00

Abstract: Disclosed herein are antibodies, pharmaceutical formulations for treating or preventing Alzheimer's disease, methods of treating or preventing Alzheimer's disease, and kits comprising pharmaceutical formulations for treating or preventing Alzheimer's Disease comprising an anti-Aβ protofibril antibody and anti-tau antibody.